The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. (Q46626071)
Jump to navigation
Jump to search
scientific article published in May 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates. |
scientific article published in May 2005 |
Statements
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates (English)
Giampietro Gasparini
Sabrina Meo
Giuseppe Comella
Simonetta Chiara Stani
Luigi Mariani
Teresa Gamucci
Giovanni Mansueto
Paola Bonginelli